Market Herald logo

Subscribe

Be the first with the news that moves the market
  • InterCure (INCR.U) has signed a licensing agreement with Praetorian Global, Inc. to distribute Binske-branded products
  • It allows InterCure to manufacture and distribute all Binske branded products under EU-GMP standards exclusively to the international pharmaceutical space
  • InterCure engages in the research, cultivation, production, and distribution of pharma-grade cannabis-based products
  • Intercure Ltd. (INCR.U) remains unchanged, trading at C$4.15 per share at 12:30 pm ET

InterCure (INCR.U) has signed a licensing agreement with Praetorian Global, Inc. to distribute Binske-branded products.

As per the agreement, Praetorian Global, Inc., based in Florida, and the parent company of the award-winning cannabis brand, Binske, has granted InterCure an exclusive multi-year right to cultivate, manufacture, market, and distribute Binske-branded products in major global pharmaceutical markets including Israel, Germany, Australia, UK and others.

InterCure believes Binske has pioneered the premium medical and recreational markets in the United States. The Binske brand has won numerous cannabis-related awards, including Leafly’s Best Overall Brand, Best Edibles and Best Concentrates.

The agreement brings these Binske-branded products exclusively to Intercure’s Israeli hub. It allows InterCure to manufacture and distribute all Binske branded products under EU-GMP standards exclusively to the international pharmaceutical space.

Binske will provide the company access to its intellectual property. It includes genetics, formulations and know-how for the cultivation and manufacturing of Binske-branded cannabis products at the company’s facilities. In addition, Binske will provide InterCure with IP relating to extraction formulations and the production of downstream products developed by Binske. It will also support InterCure’s team with training in manufacturing and cultivation methods that are tailored to Binske’s exacting standards.

InterCure engages in the research, cultivation, production, and distribution of pharma-grade cannabis-based products.

Intercure Ltd. (INCR.U) remains unchanged, trading at C$4.15 per share at 12:30 pm ET.


More From The Market Herald

" @ the Bell: Markets tumble amid rate worries

Canada’s main stock index was weighed down on Monday by commodity-linked and financial stocks. The telecom and utilities sectors posted some gains.
Dolly Varden Silver Corporation - President & CEO, Shawn Khunkhun.

" Dolly Varden Silver (TSXV:DV) reports highest-grade silver assay found so far on the Kitsault Valley Property

Dolly Varden Silver Corporation (DV) discovered the highest-grade silver assay found so far on the Kitsault Valley Property.

" Black Tusk Resources (CSE:TUSK) acquiring PegaLith Project

Black Tusk Resources (TUSK) has signed a $361,000 share purchase agreement to acquire 1396427 BC Ltd.

" Deep South Resources (TSXV:DSM) closes oversubscribed non-brokered private placement

Deep-South Resources (DSM) has closed the final tranche of an oversubscribed, non-brokered private placement for gross proceeds of $490,000.